title: JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.
abstract: This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2-kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho-JAK2 in CLE skin samples as well as the immunomodulatory in vitro effect of ruxolitinib in cultured immortalized keratinocytes and in a 3D human epidermis model (epiCS). Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.
authors.affiliation: Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
authors.forename: Anna Sophie
authors.initials: AS
authors.lastname: Klaeschen
authors.affiliation: Medical Clinic III, Hematology, Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany.
authors.forename: Dominik
authors.initials: D
authors.lastname: Wolf
authors.affiliation: Medical Clinic III, Hematology, Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Brossart
authors.affiliation: Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Bieber
authors.affiliation: Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
authors.forename: Joerg
authors.initials: J
authors.lastname: Wenzel
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism*; D005260:Female; D006801:Humans; D000075242:Janus Kinase Inhibitors / Q000627:therapeutic use*; D015603:Keratinocytes / Q000378:metabolism*; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy* / Q000378:metabolism; D009570:Nitriles; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines
chemical_list: D016207:Cytokines; D000075242:Janus Kinase Inhibitors; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib
keywords: CXCL10; JAK/STAT pathway; chilblain lupus erythematosus; interferon; kinase inhibitor